Efficacy and follow-up of humanized anti-BCMA CAR-T cell therapy in relapsed/refractory multiple myeloma patients with extramedullary-extraosseous, extramedullary-bone related, and without extramedullary disease

Wei Li | Meijing Liu | Ting Yuan | Lixiang Yan | Rui Cui | Qi Deng

1Department of Hematology, The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China
2Department of Hematology, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, China

Correspondence
Qi Deng, No. 24 Fukang Road, Nankai District, Tianjin, 300192, China.
Email: kacyjy@126.com

Funding information
The National Natural Science Foundation of China, Grant/Award Number: 81900186

Abstract
The prognosis of patients with multiple myeloma (MM) with extramedullary disease (EMD) remains poor. A high overall response rate (ORR) has been reported following anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cell therapy in relapsed/refractory (R/R) patients with MM; however, data on patients with EMD remain limited. Herein, we compared and analyzed the efficacy and long-term follow-up of anti-BCMA CAR-T cell therapy in R/R MM patients with extramedullary-extraosseous (EM-E), extramedullary-bone related (EM-B), and without extramedullary disease. No difference in the ORR was observed between the three groups. The long-term efficacy of anti-BCMA CAR-T cell therapy in the EM-E group was worse than that in patients without EMD and with EM-B. In the EM-E group, disease progression was the reappearance of extramedullary lesions without an increase in the MM cell percentage or M protein level. Although no difference in the proportion of CAR-T cells was detected among the three groups, the EM-E group might exhibit a relatively high grade of cytokine release syndrome following anti-BCMA CAR-T therapy. Interleukin-6 levels in the without EMD group were lower than those in the EM-E and EM-B groups. However, given the small number of cases in the three groups, statistical analysis was not performed. (ChiCTR1800017051 and ChiCTR2000033925).

Keywords
anti-BCMA CAR-T, efficacy, extramedullary multiple myeloma, follow-up, refractory, relapsed
1 | INTRODUCTION

Multiple myeloma (MM) is a hematologic malignancy characterized by proliferative disorders of neoplastic plasma cells. Although proteasome inhibitors, monoclonal antibodies, immunomodulatory agents, and autologous hematopoietic stem cell transplantation (auto-HSCT) could significantly improve efficacy and survival,1–3 some patients develop relapsed/refractory (R/R) MM with an extremely poor prognosis.4–6 MM cells are often not confined to bone marrow, migrating from the bone marrow, infiltrating into various extramedullary organs throughout the body, and even infiltrating the peripheral blood.7 This extramedullary MM (EMM) is a rare type of MM, with the lesion termed extramedullary disease (EMD).8 It might develop at initial diagnosis, during relapse, or follow-up. Two types of EMDs are known to exist: extramedullary-extraosseous (EM-E), leading to soft tissue tumors at a site far from the bone, and extramedullary-bone related (EM-B), which invades the surrounding soft tissues.9,10 Although several new EMD treatments are available, the prognosis of MM patients with EMD remains poor.11–13 Anti-B cell maturation antigen (anti-BCMA) is a member of the tumor necrosis factor receptor superfamily, mainly expressed in MM cells of almost all patients.14 Therefore, anti-BCMA is considered an ideal target for chimeric antigen receptor (CAR)-T cell therapy in patients with R/R MM.15,16 A high overall response rate (ORR) has been reported following anti-BCMA CAR-T cell therapy in patients with R/R MM.17,18 However, data on MM patients with EMD are limited. Herein, we compared and analyzed the efficacy, safety, and long-term follow-up of humanized anti-BCMA CAR-T cell therapy in R/R MM patients with EM-E, EM-B, and without EMD.

2 | PATIENTS AND METHODS

2.1 | Patients enrolled in the study

Twenty-one patients were diagnosed with R/R MM and enrolled in clinical trials of humanized anti-BCMA CAR-T cell therapy (ChiCTR1800017051 and ChiCTR2000033925) between September 2018 and June 2020, including six patients with at least one EM-E, six patients with at least one EM-B, and nine patients without any assessable EMD. All patients had BCMA expression in MM cells at enrollment. The cutoff date was 31 July 2021. All patients were observed after anti-BCMA CAR-T cell therapy for more than 12 months unless death occurred due to R/R MM.

2.2 | Preparation of humanized anti-BCMA CAR-T cells and anti-BCMA CAR-T cell therapy

Peripheral blood mononuclear cells were collected from patients with R/R MM and isolated by Ficoll density gradient centrifugation. CD3+ T cells were selected using CD3 microbeads (Miltenyi Biotec, Inc.). CD3+ T cells (5 × 10^6) were transduced with lentiviral supernatant from 293T cells transfected with humanized anti-BCMA CAR plasmid (20 μg, lenti-BCMA-2rd-CAR; Shanghai Genbase Biotechnology Co. Ltd.). On day 12–15 cultivation, transduction efficiencies of anti-BCMA CAR were analyzed by flow cytometry (FCM) (BD Biosciences).

Before anti-BCMA CAR-T cell infusion, all patients with R/R MM received lymphodepleting chemotherapy with fludarabine (30 mg/m^2) and cyclophosphamide (400 mg/m^2) from day 4 to day 2. All patients received autologous humanized anti-BCMA CAR-T cells (2 × 10^6 cells/kg) on day 0. No patient received auto-HSCT after anti-BCMA CAR-T cell therapy.

2.3 | Criteria for diagnosis and evaluation criteria for therapeutic efficacy

Diagnoses of R/R MM and EM-E and EM-B and clinical response to the humanized anti-BCMA CAR-T cell therapy were assessed according to the International Myeloma Working Group Guidelines uniform response criteria for MM.19 Herein, the proportion of MM cells was determined using bone marrow morphology and flow cytometric analysis. M protein levels were detected using immunofixation electrophoresis. EM-E and EM-B were detected using computed-tomography, positron emission tomography, and magnetic resonance imaging. MM cells in the pleural effusion were detected using FCM.

The therapeutic efficacy of all patients with R/R MM was evaluated monthly after anti-BCMA CAR-T cell infusion in the first three months; then, efficacy was evaluated every three months. The follow-up was performed from the date of humanized anti-BCMA CAR-T cell infusion until patient death or study cutoff date. Clinical responses included stringent complete response (sCR), complete response (CR), very good partial response (VGPR), partial response (PR), minimal response, stable disease (SD), and progressive disease. ORR (sCR, CR, VGPR, and PR), overall survival (OS), and progression-free survival (PFS) were also assessed.

2.4 | Adverse events following humanized anti-BCMA CAR-T cell therapy

We evaluated Adverse events (AEs) associated with humanized anti-BCMA CAR-T cell therapy. The grade of cytokine release syndrome (CRS) was determined according to the National Cancer Institute Common Terminology Criteria for Adverse Events v4.03.20 Immune effector cell-associated neurotoxicity syndrome (ICANS) was used to assess neurotoxicity.21 FCM was used to assess the proportion of anti-BCMA CAR-T cells in peripheral blood on days 0, 4, 7, 14, 28, and 60 after infusion; the proportion of these cells was also determined in pleural effusion. Cytokine levels, including interleukin-6 (IL-6), IL-2R, and
tumor necrosis factor-α (TNF-α), were assessed on days 0, 7, 14, 28, and 60 using enzyme-linked immunosorbent assay.

2.5    Statistical analysis

Data are expressed as the mean ± standard error (SE). Probabilities of PFS and OS were estimated using the Kaplan-Meier method and compared using the log-rank test. All statistical analyses were performed using GraphPad Prism 7 and SPSS 17.0. Statistical significance was set at $p < 0.05$.

3    RESULTS

3.1    Characteristics of patients with R/R MM

Table 1 lists the characteristics of patients with R/R MM enrolled in our study. At enrollment, all patients with R/R MM showed BCMA expression in MM cells, determined by FCM.

3.2    Transduction and amplification efficiency, infusion dose of humanized anti-BCMA CAR-T cells

The mean humanized anti-BCMA CAR transduction efficiency for final products of the EM-E, EM-B, and without EMD group were 37.87 ± 9.65%, 36.32 ± 8.04%, and 39.57 ± 9.08%, respectively. On harvesting anti-BCMA CAR-T cells, the mean number of cells for the three groups was $(4.05 ± 1.82 \times 10^6)$, $(3.68 ± 1.24 \times 10^6)$, and $(4.37 ± 0.81 \times 10^6)$ cells/kg. On day 0, all groups received a dose of $(2.18 ± 0.41 \times 10^6)$, $(2.08 ± 0.19 \times 10^6)$, and $(2.05 ± 0.15 \times 10^6)$ cells/kg autologous humanized anti-BCMA CAR-T cell infusion.

3.3    Clinical response to humanized anti-BCMA CAR-T therapy

We evaluated the efficacy of all 21 patients with R/R MM every month after anti-BCMA CAR-T cell infusion. The median time to reach optimal response was 2.5 months (1–4 months), 2.8 months (2–4 months), and 2.3 months (1–4 months), while ORRs were 83.33%, 83.33%, and 88.89% in EM-E, EM-B, and without EMD groups, respectively (Figure 1A). No difference in ORR was noted between the three groups ($p = 0.937$).

MM cell percentages in the bone marrow and M protein levels in peripheral blood were determined after anti-BCMA CAR-T cell infusion (Figure 1B,C). Except for patient 4 in the without EMD group ($Pt_{without}$ 4), who achieved SD following anti-BCMA CAR-T cell therapy, the MM cell percentages in the bone marrow and M protein levels in peripheral blood decreased to different degrees in all patients with R/R MM anti-BCMA CAR-T cell infusion. In all patients with R/R MM who reached ORR, no MM cells were detected in the bone marrow, and the M protein level decreased to varying degrees.

MM cells in the bone marrow and M protein levels in two patients who reached PD and SD in the EM-E and EM-B groups exhibited the same characteristics as patients who reached ORR. However, the MM cell percentage and M protein level of the $Pt_{without}$ 4 who reached SD failed to decline after anti-BCMA CAR-T cell therapy.

In EM and EB groups, assessable EMD of patients with R/R MM who reached ORR disappeared or shrunk on reaching optimal response. However, it failed to shrink in patients who did not achieve the ORR.

3.4    Disease re-progression after anti-BCMA CAR-T cell therapy

On disease re-progression after anti-BCMA CAR-T cell therapy, we assessed the proportion of bone marrow MM cells and M protein level in peripheral blood. In the EM-E group, the proportion of MM cells and M protein level increased again in patient 2 ($Pt_{EM-E}$ 2) when EMD recurred. However, no increase was detected in the proportion of MM cells and M protein level in $Pt_{EM-E}$ 1, 4, 5, and 6 following EMD recurrence. In these patients, disease progression was noted as the reappearance of EM lesions (both primary and new sites). In the EM-B group, the proportion of MM cells and M protein level increased again with EMD recurrence in patient 3 ($Pt_{EM-B}$ 3) and $Pt_{EM-B}$ 6. In the control group, the proportion of MM cells and M protein level increased again in $Pt_{without}$ 4, 6, and 8 following disease re-progression (Figure 1B and C).

In EM-E and EM-B groups, all patients with R/R MM who attained the ORR showed the original EMD volume enlargement or the emergence of new EMD following disease re-progression. In bone marrow MM cells, anti-BCMA expression was analyzed by FCM following disease re-progression. Anti-BCMA expression in detectable bone marrow MM cells was positive or weakly positive in these patients.

3.5    Survival time following humanized anti-BCMA CAR-T therapy

During follow-up after the optimal response time, four patients in the EM-E group and two in the EM-B group showed disease progression and died due to primary disease. Although three patients in the without EMD group showed disease progression, two died owing to the primary disease; the other patient died of other factors (cerebrovascular disease) (Figure 2).

PFS rates in patients with R/R MM were 50%, 83.33%, and 88.89% in the EM-E, EM-B, and without EMD groups, respectively, after 180 days of CAR-T cell infusion; after 360 days, PFS rates were 16.67%, 66.67%, and 66.67%, respectively. OS rates in the patients with R/R MM were 83.33%, 100%, and 88.89% in the EM-E, EM-B, and without EMD groups, respectively, after 180 days of CAR-T cell infusion; after 360 days, OS rates were 33.33%, 83.33%, and 88.89%,
| Sex (F/M) | Age | KPS | Subtype | ISS | Extramedullary disease | Time of extramedullary disease from diagnosis (months) | High-risk Cytogenetics | Numbers of Prior therapy | Murine BCMA CAR-T cell therapy before | Auto-HSCT or radiotherapy before |
|-----------|-----|-----|---------|-----|-------------------------|-----------------------------------------------|------------------------|--------------------------|---------------------------------|---------------------------------|
| EM-E      | 1 M | 57  | 90      | k light chain | III | EM-E/EM-E               | 5                                               | t(4;14), t(14;16), Del(17p) | 14                             | No                              | HSCT (1 time)                  |
|           | 2 F | 69  | 80      | IgG-λ        | III | EM-E                    | 5                                               | t(4;14)                | 9                           | No                              | No                              |
|           | 3 M | 59  | 100     | k light chain | III | EM-E/EM-E               | 4                                               | t(14;16)               | 8                           | Yes                             | Radiotherapy                   |
|           | 4 F | 53  | 90      | IgG-κ        | II  | EM-E/EM-E               | 5                                               | t(14;16)               | 9                           | No                              | Radiotherapy                   |
|           | 5 F | 38  | 90      | k light chain | II  | EM-E/EM-E               | 6                                               | None                   | 17                          | No                              | HSCT (2 times)                 |
|           | 6 F | 55  | 80      | IgG-λ        | III | EM-E                    | 5                                               | Del(17p), t(14;16)      | 14                          | No                              | No                              |
| EM-B      | 1 F | 52  | 90      | IgG-λ        | III | EM-B                    | 6                                               | t(14;16)               | 14                          | No                              | HSCT (2 times)                 |
|           | 2 F | 55  | 90      | IgG-κ        | II  | EM-B                    | 3                                               | Del(17p), t(4;14)      | 10                          | No                              | Radiotherapy                   |
|           | 3 F | 71  | 80      | IgD-λ        | III | EM-B                    | 4                                               | Del(17p)               | 17                          | No                              | Radiotherapy                   |
|           | 4 M | 45  | 100     | k light chain | II  | EM-E                    | 9                                               | None                   | 7                           | No                              | HSCT (2 times)                 |
|           | 5 M | 61  | 90      | k light chain | II  | EM-B                    | 7                                               | t(14;16)               | 9                           | No                              | HSCT (1 time)                  |
|           | 6 F | 67  | 80      | IgG-λ        | III | EM-E                    | 5                                               | Del(17p), t(4;14)      | 13                          | No                              | No                              |
| EMD-      | 1 F | 69  | 80      | IgG-λ        | II  | -                       | -                                               | t(14;16)               | 13                          | No                              | No                              |
|           | 2 M | 58  | 100     | k light chain | III | -                       | -                                               | t(4;14)               | 11                          | No                              | No                              |
|           | 3 M | 63  | 80      | IgG-λ        | III | -                       | -                                               | t(14;16)               | 5                           | No                              | HSCT (1 time)                  |
|           | 4 M | 66  | 90      | IgA-κ        | II  | -                       | -                                               | t(14;16), Del(17p)     | 16                          | No                              | No                              |
|           | 5 F | 55  | 90      | IgG-λ        | II  | -                       | -                                               | None                   | 7                           | No                              | No                              |
|           | 6 F | 52  | 90      | IgA-λ        | II  | -                       | -                                               | Del(17p)               | 10                          | No                              | HSCT (1 time)                  |
|           | 7 F | 72  | 80      | IgG-κ        | III | -                       | -                                               | t(14;16)               | 8                           | No                              | No                              |
|           | 8 F | 77  | 80      | IgG-κ        | III | -                       | -                                               | None                   | 13                          | No                              | No                              |
|           | 9 F | 42  | 100     | IgG-κ        | III | -                       | -                                               | t(14;16)               | 5                           | No                              | No                              |

Abbreviations: BCMA, anti-B-cell maturation antigen; EM-B, Extramedullary-bone related; EMD-, Without extramedullary disease group; EM-E, Extramedullary-extraosseous; HSCT, hematopoietic stem cell transplantation; ISS, International Staging System; KPS, Karnofsky Performance Scale.
respectively. Given the small number of cases in the three groups, statistical analysis was not performed.

3.6 | Proportions of humanized anti-BCMA CAR-T cells in peripheral blood

The proportion of anti-BCMA CAR-T cells was detected at days 0, 4, 7, 14, 28, and 60 by FCM after CAR-T cell infusion (Figure 3A-C). For CD3+ T cells in peripheral blood, the median expansion peak of the anti-BCMA CAR-T cells was 37.4 (interquartile range [IQR] 25.8, 53.3)% in the EM-E group, 31.5 (IQR 25.4, 32.7)% in the EM-B group, and 25.9 (IQR 8.8–38.4)% in the EM group. Expansion peaks of humanized anti-BCMA CAR-T cells in the three groups are shown in Figure 3D.

3.7 | Safety and adverse effects

CRS and ICANS grades in the three groups receiving anti-BCMA-CAR-T cell therapy is listed in Table 2. No patient died from CRS or ICANS during therapy. Grade 3 and 4 CRS and grade 2
FIGURE 2  The survival observation of the humanized anti-BCMA CAR-T cell therapy

FIGURE 3  The proportions of the anti-BCMA CAR-T cells in the therapy. (A–C) The proportions of humanized anti-BCMA CAR T cells in peripheral blood in the three groups. (D) There was no difference in the expansion peaks of the CAR-T cells in the three groups.
ICANS were detected in the EM-E and EM-B groups, respectively.

**TABLE 2** The grades of CRS and ICANS in anti-BCMA-CAR T cell therapy

|     | EM-E (EMD group) | EM-B (EMD group) | Without EMD group |
|-----|------------------|------------------|-------------------|
|     | CRS   | ICANS | CRS   | ICANS | CRS   | ICANS |
| P#1 | 1     | 0     | 1     | 0     | 2     | 0     |
| P#2 | 3     | 2     | 2     | 0     | 1     | 0     |
| P#3 | 2     | 1     | 4     | 2     | 1     | 0     |
| P#4 | 2     | 0     | 1     | 0     | 1     | 0     |
| P#5 | 3     | 0     | 2     | 0     | 1     | 0     |
| P#6 | 4     | 2     | 3     | 0     | 1     | 0     |
| P#7 |       | 2     | 0     |       |       |       |
| P#8 | 2     | 1     |       |       |       |       |
| P#9 |       | 2     | 0     |       |       |       |

Abbreviations: CRS, cytokine release syndrome; EM-E, Extramedullary-extraosseous; EM-B, Extramedullary-bone related, EMD, Without extramedullary disease group; ICANS, Immune effector cell-associated neurotoxicity syndrome.

IL-6, TNF-α, and IL-2R levels peaked 4–7 days after anti-BCMA CAR-T cell infusion. Peaks of IL-6, TNF-α, and IL-2R are shown in Figure 4A–C. Herein, IL-6 peaks were markedly high in most patients in the EM-E and EM-B groups. IL-2R peaks in patients with R/R MM in the without EMD group were lower than those in EM-E and EM-B groups. Given the small number of cases in the three groups, statistical analysis was not performed.

Following anti-BCMA CAR-T cell therapy, patients developed fever with or without chills, fatigue, edema, headache, nausea, tachycardia, and other symptoms 4–8 days after infusion. These symptoms recovered 16–42 days after CAR-T cell infusion. Hematologic toxicity was deemed grade 1–4 in the anti-BCMA CAR-T cell therapy, occurring from 7 to 12 days and recovered 18–60 days after CAR-T cell infusion (Table 3). No patient died from secondary infections due to hematologic toxicity.

The patients received methylprednisolone, antipyretic drugs, and symptomatic therapy to overcome their AEs. Patients in the EM-E and EM-B groups diagnosed with grade 3 and 4 CRS received tocilizumab during therapy. In addition, patients in the EM-E and EM-B groups diagnosed with grade 2 ICANS received dexamethasone to overcome serious AEs. No patient in the control group received tocilizumab or dexamethasone in our study.

**FIGURE 4** The serum level of IL-6, TNF-α and IL-2R
EMD is defined as the proliferation of malignant MM cells outside the confines of bone marrow. In addition, EMD should exclude plasma cell leukemia and solitary plasmacytomas. It should be noted that EMD can develop at the time of initial diagnosis (15% incidence), at relapse, or during follow-up (20% incidence). However, data are limited in terms of incidence, prevalence, clinical characteristics, laboratory characteristics, and response to new drugs for EMD. Currently, no guidelines are available for the treatment of MM patients with EMD. In previous reports, the OS of patients with EMM did not typically exceed 3 years. In a recent retrospective multi-institutional study, autologous stem cell transplant showed a survival benefit for both EM-E and EM-B. However, the prognosis of MM patients with EMD is poor, even with HSCT, and survival typically does not exceed 3 years. In particular, the median OS of patients with relapse after auto-HSCT was less than 1 year. Some studies have suggested that following the use of proteasome inhibitors and/or immunomodulatory agents, the PFS and OS of patients with EMM were less pronounced than those in MM patients without EMD. In general, the prognosis for EM-E is worse than EM-B.

Anti-BCMA CAR-T cell therapy showed satisfactory efficacy and prolonged the survival time of patients with R/R MM in previous clinical trials. The ORR of anti-BCMA CAR-T cell therapy was 85%, with 45% of patients reaching CR. What is the efficacy of anti-BCMA CAR-T cells in the treatment of patients with R/R MM with EMD? The PFS and OS of R/R MM patients with EMD were lower than those of R/R MM patients without EMD. However, clinical data are limited, except for a few case reports or a subset of EMD patients in clinical trials. The efficacy and safety of anti-BCMA CAR-T cells in the two types of R/R MM patients with EMD (EM-E and EM-B) have been rarely reported.

Herein, we compared and analyzed the efficacy and follow-up of humanized anti-BCMA CAR-T cell therapy in R/R MM patients with EM-E, EM-B, and without EMD. First, we observed no difference in ORRs between the EM-E, EM-B, and without EMD groups on evaluating the efficacy of all 21 patients with R/R MM. However, we noted differences in survival time between the EM-E, EM-B, and without EMD groups after humanized anti-BCMA CAR-T therapy.
ACKNOWLEDGMENTS

We thank all our patients for their participation in our clinical trials.

We thank the Shanghai Genbase Biotechnology Co., Ltd. for providing us with anti-BCMA CAR-T cells.

CONFLICT OF INTEREST

All authors have no conflict of interest to report.

ETHICS STATEMENT

This study was approved by the Medical Ethics Committee of the Department of Hematology, Tianjin First Center Hospital (Tianjin, China). (Approved No. of ethic committee: 2015002X and 2020N028KY). The Clinical trial in our study was registered at http://www.chictr.org.cn/index.aspx as ChiCTR2000033925. The patient gave their written informed consent in accordance with the Declaration of Helsinki. The patients agreed to have their data used in our study.

AUTHOR CONTRIBUTION

Concept and design: Qi Deng. Drafted or revised the manuscript: Wei Li, Meijing Liu, Ting Yuan and Rui Cui. Acquisition of data: Wei Li and Lixiang Yan. Analysis and interpretation of data: Wei Li. Writing, review and/or revision of manuscript: Wei Li. Study supervision: Qi Deng.

DATA AVAILABILITY STATEMENT

All data generated or analyzed during our study are included in this published article.

ORCID

Wei Li https://orcid.org/0000-0002-7526-6626
Rui Cui https://orcid.org/0000-0002-4994-5262
Qi Deng https://orcid.org/0000-0002-3646-4953

PEER REVIEW

The peer review history for this article is available at https://publons.com/publon/10.1002/hon.2958.

REFERENCES

1. Avet-Loiseau H, Bahlis NJ, Chng WJ, et al. Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients. Blood. 2017;130(24):2610-2618.
2. Spencer A, Lentzschi S, Weisel K, et al. Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR. Haematologica. 2018;103(12):2079-2087.
3. Mateos MV, Dimopoulos MA, Cavo M, et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med. 2018;378(6):518-528.
4. Kumar SK, Dimopoulos MA, Kastritis E, et al. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome some inhibitors: a multicenter IMWG study. Leukemia. 2017;31(11):2443-2448.
5. Moreau P. How I treat myeloma with new agents. Blood. 2017; 130(13):1507-1513.
6. Lonial S, Boise LH, Kaufman J. How I treat high-risk myeloma. Blood. 2015;126(3):1536-1543.
7. Vande Broek I, Vanderkerken K, Van Camp B, Van Riet I. Extravasation and homing mechanisms in multiple myeloma. Clin Exp Metastasis. 2008;25(3):325-334.
8. Weinstock M, Gobral ML, Extramedullary multiple myeloma. Leuk Lymphoma. 2013;54(6):1135-1141.
9. Touzeau C, Moreau P. How I treat extramedullary myeloma. Blood. 2016;2015;127(8):971-976.
10. Blade J, Fernandez de Larrea C, Rosinol L, Cibeira MT, Jiménez R, Powles R. Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach. J Clin Oncol. 2011;29(28):3805-3812.
11. Bhutani M, Foureau DM, Atrash S, Voorhees PM, Usmani SZ. Extramedullary multiple myeloma. Leukemia. 2020;34(1):1-20.
12. Usmani SZ, Heuck C, Mitchell A, et al. Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents. Bone Marrow Transplant. 2012;9761-1761. https://pubmed.ncbi.nlm.nih.gov/22689675/
13. Smith EL, Mailankody S, Staehr M, et al. BCMA-targeted CAR T-cell therapy plus radiotherapy for the treatment of refractory myeloma reveals potential synergy. Cancer Immunol Res. 2019;7(7):1047-1053.

14. Hosen N. Chimeric antigen receptor T-cell therapy for multiple myeloma. Cancers. 2019;11(12):2024.

15. Tai YT, Mayes PA, Acharya C, et al. Novel anti-B-cell maturation antigen antibody-drug conjugate selectively induces killing of multiple myeloma. Blood. 2014;123(20):3128-3138. https://pubmed.ncbi.nlm.nih.gov/24569262/

16. Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538-e548.

17. Raje N, Berdeja J, Lin Y, et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019;380(18):1726-1737.

18. Cohen AD, Garfall AL, Stadtmauer EA, et al. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. J Clin Invest. 2019;129(6):2210-2221.

19. Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33(26):2863-2869.

20. Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124(2):188-195. https://pubmed.ncbi.nlm.nih.gov/24876563/

21. Lee DW, Santomasso BD, Lockle FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transpl. 2019;25(4):625-638.

22. Bladé J, Lust J, Kyle RA. Immunoglobulin D multiple myeloma: presenting features response to therapy, and survival in a series of 53 cases. J Clin Oncol. 1994;12(11):2398-2404.

23. Bladé J, Kyle RA, Greipp PR. Presenting features and prognosis in 72 patients with multiple myeloma who were younger than 40 years. Br J Haematol. 1996;93(2):345-351.

24. Varga C, Xie W, Laubach J, et al. Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations. Br J Haematol. 2015;169(6):843-850.

25. Usmani SZ, Rodriguez-Otero P, Bhutani M, Mateos M-V, Miguel JS. Defining and treating high-risk myeloma. Leukemia. 2015;29(11):2119-2125. https://pubmed.ncbi.nlm.nih.gov/26265183/

26. Sonneveld P, Avet-Loiseau H, Lonial S, et al. Treatment of multiple myeloma with high risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016;127(24):2955-2962.

27. Jagosky MH, Usmani SZ. Extramedullary disease in multiple myeloma. Curr Hematol Malig Rep. 2020;15(2):72-71.

28. Beksc M, Seval GC, Kanellas N, et al. A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome. Haematologica. 2020;105(1):201-208.

29. Varettoni M, Corso A, Pica G, Mangiacavalli S, Pascutto C, Lazzarino M. Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol. 2010;21(2):325-330.

30. Oriol A. Multiple myeloma with extramedullary disease. Adv Ther. 2011;28(Suppl 7):1-6.

31. Pour L, Sevcikova S, Greslikova H, et al. Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse. Haematologica. 2014;99(2):360-364.

32. Kumar L, Gorgi R, Patel AK, et al. Multiple myeloma with extramedullary disease: impact of autologous stem cell transplantation on outcome. Bone Marrow Transpl. 2017;52(10):1473-1475.

33. Mangiacavalli S, Pompa A, Ferretti V, et al. The possible role of burden of therapy on the risk of myeloma extramedullary spread. Ann Hematol. 2017;96(1):73-80.

34. Rosioli L, Beksc M, Zagnini E, et al. Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. Br J Haematol. 2021;194(3):496-507.

35. Susanibar Adaniya SP, Cohen AD, Garfall AL. Chimeric antigen receptor T cell immuno-therapy for multiple myeloma: a review of current data and potential clinical applications. Am J Hematol. 2019;94(S1):S28-S33.

36. Zhang MM, Zhou LH, Zhao HL, et al. Risk factors associated with durable progression-free survival in relapsed or refractory multiple myeloma patients treated with anti-BCMA CAR-T cell therapy. Clin Cancer Res. 2021;27(23):6384-6392. https://doi.org/10.1158/1078-0432.ccr-21-0301

37. Deng H, Liu M, Yuan T, et al. Efficacy of humanized anti-BCMA CAR T cell therapy in relapsed/refractory multiple myeloma patients with and without extramedullary disease. Front Immunol. 2021;12:720571. https://doi.org/10.3389/fimmu.2021.720571

38. Wang D, Wang J, Hu G, et al. A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma. Blood. 2021;137(21):2890-2901.

39. Qian Y, Qian Z, Zhao X, et al. Successful treatment of relapsed/refractory extramedullary multiple myeloma with anti-BCMA CAR-T cell therapy followed by haploidentical hematopoietic stem cell transplantation: a case report and a review of the contemporary literature. Front Med (Lausanne). 2021;7(8):649824.

40. Xu J, Chen LJ, Yang SS, et al. Exploratory trial of a biepitopic CAR T cell therapy in relapsed/refractory multiple myeloma patients with and without extramedullary disease. Front Immunol. 2021;12:720571. https://doi.org/10.3389/fimmu.2021.720571

41. Brudno JN, Maric I, Hartman SD, et al. T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma. J Clin Oncol. 2018;36(22):2267-2280.